Gilead Sciences Stock Analysis (Episode010)
The DIY Investing Podcast · Trey Henninger: Private Investor, Portfolio Manager, Business Strategist, and Value Investing Expert
Audio is streamed directly from the publisher (pdcn.co) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Gilead Sciences is a biopharmaceutical company with a focus on treating and curing diseases. Their areas of focus include HIV, Hepatitis C, Oncology, Inflammation, and NASH.
Gilead Sciences (GILD)- Business Model Overview
- HIV
- Hepatitis C
- Oncology/Cancer Treatment (KITE) – Yescarta
- Inflammation - Filgotinib
- NASH (Liver disease) – Selonsertib
- Leading cause of liver transplants. Generally related to Obesity
- Durability
- Competition
- Quality and Growth
- Capital Allocation
- Value
- Potential Errors
- Conclusion
The full show notes for this episode, including my outline for today's podcast, are available at https://www.diyinvesting.org/Episode6
Please review and rate the podcastIf you enjoyed this podcast and found it helpful, please consider leaving me a review. On an iOS platform such as an iPhone or iPad, you can do so by following these steps:
- In your podcast app, click the search icon that looks like a magnifying glass in the bottom right-hand corner.
- Type "The DIY Investing" into the search bar. This podcast should be one of the first shows that display.
- Select the podcast show icon.
- Scroll down to the "Ratings & Reviews Section" and click on the button that says "Write a Review".
- Write a short one or two sentence review and give me a rating that matches how you feel about the podcast.